Richard A. Miller 13D and 13G filings for Corvus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 4:30 pm Purchase |
2024-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
Richard A. Miller | 5,220,368 7.700% |
1,536,358 (+41.70%) |
Filing |
| 2024-02-13 6:27 pm Purchase |
2023-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
Richard A. Miller | 3,684,010 7.190% |
578,889 (+18.64%) |
Filing |
| 2023-02-10 4:00 pm Purchase |
2022-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
Richard A. Miller | 3,105,121 6.450% |
497,973 (+19.10%) |
Filing |
| 2022-02-11 5:55 pm Purchase |
2021-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
Richard A. Miller | 2,607,148 5.450% |
427,589 (+19.62%) |
Filing |
| 2021-02-12 9:18 pm Purchase |
2020-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
Richard A. Miller | 2,179,559 7.500% |
220,417 (+11.25%) |
Filing |